JP7526101B2 - 誘導性キメラサイトカイン受容体 - Google Patents

誘導性キメラサイトカイン受容体 Download PDF

Info

Publication number
JP7526101B2
JP7526101B2 JP2020568943A JP2020568943A JP7526101B2 JP 7526101 B2 JP7526101 B2 JP 7526101B2 JP 2020568943 A JP2020568943 A JP 2020568943A JP 2020568943 A JP2020568943 A JP 2020568943A JP 7526101 B2 JP7526101 B2 JP 7526101B2
Authority
JP
Japan
Prior art keywords
cells
receptor
domain
cell
chimeric cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514677A (ja
JP2021514677A5 (enExample
Inventor
アンドリュー ロス ネガー
スペンサー パーク
リガーズ ハビエル フェルナンド チャパロー
レジーナ ジュンフィ リン
ブラーコム トーマス ジョン バン
Original Assignee
アロジーン セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アロジーン セラピューティクス，インコーポレイテッド filed Critical アロジーン セラピューティクス，インコーポレイテッド
Publication of JP2021514677A publication Critical patent/JP2021514677A/ja
Publication of JP2021514677A5 publication Critical patent/JP2021514677A5/ja
Priority to JP2024029998A priority Critical patent/JP7793667B2/ja
Application granted granted Critical
Publication of JP7526101B2 publication Critical patent/JP7526101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020568943A 2018-03-02 2019-03-01 誘導性キメラサイトカイン受容体 Active JP7526101B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024029998A JP7793667B2 (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637600P 2018-03-02 2018-03-02
US62/637,600 2018-03-02
PCT/US2019/020340 WO2019169290A1 (en) 2018-03-02 2019-03-01 Inducible chimeric cytokine receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024029998A Division JP7793667B2 (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Publications (3)

Publication Number Publication Date
JP2021514677A JP2021514677A (ja) 2021-06-17
JP2021514677A5 JP2021514677A5 (enExample) 2022-03-10
JP7526101B2 true JP7526101B2 (ja) 2024-07-31

Family

ID=65952060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020568943A Active JP7526101B2 (ja) 2018-03-02 2019-03-01 誘導性キメラサイトカイン受容体
JP2024029998A Active JP7793667B2 (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024029998A Active JP7793667B2 (ja) 2018-03-02 2024-02-29 誘導性キメラサイトカイン受容体

Country Status (14)

Country Link
US (2) US12163169B2 (enExample)
EP (1) EP3759132A1 (enExample)
JP (2) JP7526101B2 (enExample)
KR (2) KR20250123938A (enExample)
CN (1) CN111819192A (enExample)
AR (1) AR114273A1 (enExample)
AU (2) AU2019227979B2 (enExample)
BR (1) BR112020017734A2 (enExample)
CA (1) CA3091681A1 (enExample)
IL (2) IL276831B2 (enExample)
MX (2) MX2020009051A (enExample)
SG (1) SG11202007771VA (enExample)
TW (1) TWI897846B (enExample)
WO (1) WO2019169290A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024074801A (ja) * 2018-03-02 2024-05-31 アロジーン セラピューティクス，インコーポレイテッド 誘導性キメラサイトカイン受容体

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
EP3433269B1 (en) 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
AU2020232216B2 (en) 2019-03-01 2025-09-25 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
PE20211902A1 (es) * 2019-03-01 2021-09-27 Allogene Therapeutics Inc Receptores de citocinas quimericos constitutivamente activos
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US12528856B2 (en) 2019-08-30 2026-01-20 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising TGF β binding domains
EP4041893A4 (en) * 2019-10-08 2023-08-30 Provincial Health Services Authority CHEMERACY CYTOKINE RECEPTORS
KR20220141299A (ko) * 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
MX2022010340A (es) * 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.
EP4110355A1 (en) * 2020-02-24 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
CN115427440A (zh) 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
JP2023535371A (ja) * 2020-07-17 2023-08-17 シミュレックス インコーポレイテッド 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法
EP4267601A1 (en) * 2020-12-23 2023-11-01 Quell Therapeutics Limited Inducible signalling protein
TW202246492A (zh) * 2021-02-24 2022-12-01 中國大陸商杭州啟函生物科技有限公司 用於增強的免疫療法的系統和方法
KR102829018B1 (ko) 2021-03-03 2025-07-04 서울대학교산학협력단 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도
AU2022254143A1 (en) * 2021-04-07 2023-11-23 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
CN113512125B (zh) * 2021-04-26 2024-01-19 北京双赢科创生物科技有限公司 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
JPWO2023276395A1 (enExample) * 2021-06-28 2023-01-05
AU2022348588A1 (en) 2021-09-17 2024-04-04 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
EP4453022A1 (en) 2021-12-22 2024-10-30 Quell Therapeutics Limited Constitutive cytokine receptors
EP4499680A1 (en) 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
AU2023297866A1 (en) * 2022-06-28 2024-12-12 Resolution Therapeutics Limited Switch receptors and modified immune cells
EP4554972A1 (en) * 2022-07-11 2025-05-21 The Board of Trustees of the Leland Stanford Junior University Tunable cytokine receptor signaling domains
CN114949000B (zh) * 2022-08-02 2022-10-04 卡瑞济(北京)生命科技有限公司 麝香提取物及其增强car-t细胞疗效的应用
CN117683139A (zh) * 2022-09-09 2024-03-12 信达细胞制药(苏州)有限公司 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
CN120981484A (zh) 2023-01-23 2025-11-18 汉诺威医学院 抗entpd3嵌合抗原受体
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
CN121586727A (zh) 2023-06-21 2026-02-27 圭尔医疗有限公司 组成型细胞因子受体
KR20260033032A (ko) * 2023-06-29 2026-03-10 디스패치 바이오테라퓨틱스, 인크. 합성 시토카인 수용체
CN121620529A (zh) * 2023-07-31 2026-03-06 南京传奇生物科技有限公司 嵌合细胞因子受体及其使用方法
WO2025064779A1 (en) * 2023-09-20 2025-03-27 University Of Southern California Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others
WO2025076134A1 (en) * 2023-10-03 2025-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use
AU2024372734A1 (en) 2023-10-30 2026-04-16 Allogene Therapeutics, Inc. Engineered cells
WO2025096643A1 (en) * 2023-11-01 2025-05-08 Baylor College Of Medicine Reverse fate receptors to enhance the efficacy of engineered t cells
WO2025111277A2 (en) * 2023-11-20 2025-05-30 Carisma Therapeutics Inc. Compositions and methods relating to redirected soluble modulators
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512183A (ja) 2011-04-08 2014-05-22 ベイラー カレッジ オブ メディスン キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
JP2017531430A (ja) 2014-10-07 2017-10-26 セレクティスＣｅｌｌｅｃｔｉｓ Ｃａｒによって誘導される免疫細胞の活性を調節するための方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
IL114825A0 (en) 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2007075899A2 (en) 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
CA2738031C (en) 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011069004A1 (en) 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
WO2016127257A1 (en) 2015-02-12 2016-08-18 University Health Network Chimeric antigen receptors
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
US20180318303A1 (en) 2015-04-15 2018-11-08 Promedior, Inc. Methods for treating myeloproliferative disorders
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
KR20230167769A (ko) 2016-08-26 2023-12-11 베이롤 칼리지 오브 메드신 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
MA46862A (fr) 2016-11-17 2019-09-25 Bluebird Bio Inc Convertisseur de signaux tgf béta
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
GB201702617D0 (en) 2017-02-17 2017-04-05 Autolus Ltd Receptor
KR102879522B1 (ko) 2017-03-03 2025-11-04 엑수마 바이오테크, 코포레이션 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
EP3735460A4 (en) * 2017-09-18 2021-08-11 Exuma Biotech Corp. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
CN111819192A (zh) 2018-03-02 2020-10-23 艾洛基治疗公司 可诱导的嵌合细胞激素受体
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
PE20211902A1 (es) 2019-03-01 2021-09-27 Allogene Therapeutics Inc Receptores de citocinas quimericos constitutivamente activos
AU2020232216B2 (en) 2019-03-01 2025-09-25 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512183A (ja) 2011-04-08 2014-05-22 ベイラー カレッジ オブ メディスン キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
JP2017531430A (ja) 2014-10-07 2017-10-26 セレクティスＣｅｌｌｅｃｔｉｓ Ｃａｒによって誘導される免疫細胞の活性を調節するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg Med Chem，2001年，pp.557-562

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024074801A (ja) * 2018-03-02 2024-05-31 アロジーン セラピューティクス，インコーポレイテッド 誘導性キメラサイトカイン受容体

Also Published As

Publication number Publication date
JP2021514677A (ja) 2021-06-17
KR20250123938A (ko) 2025-08-18
CN111819192A (zh) 2020-10-23
AR114273A1 (es) 2020-08-12
KR102842692B1 (ko) 2025-08-04
BR112020017734A2 (pt) 2020-12-29
AU2019227979A1 (en) 2020-08-27
IL276831B1 (en) 2024-12-01
JP2024074801A (ja) 2024-05-31
EP3759132A1 (en) 2021-01-06
JP7793667B2 (ja) 2026-01-05
MX2025009955A (es) 2025-09-02
US12163169B2 (en) 2024-12-10
IL317065A (en) 2025-01-01
TWI897846B (zh) 2025-09-21
SG11202007771VA (en) 2020-09-29
IL276831A (en) 2020-10-29
KR20200128054A (ko) 2020-11-11
MX2020009051A (es) 2020-12-03
WO2019169290A1 (en) 2019-09-06
RU2020128082A (ru) 2022-04-04
IL276831B2 (en) 2025-04-01
US20190292533A1 (en) 2019-09-26
AU2024278090A1 (en) 2025-01-09
TW201945402A (zh) 2019-12-01
AU2019227979B2 (en) 2024-09-05
CA3091681A1 (en) 2019-09-06
US20250333719A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
JP7793667B2 (ja) 誘導性キメラサイトカイン受容体
EP3341410B1 (en) Chimeric antigen receptors with integrated controllable functions
TWI694149B (zh) 改良之ｔ細胞組成物及方法
KR20210136042A (ko) Pd-1 엑토도메인을 보유하는 키메라 사이토카인 수용체
AU2015254595B2 (en) CS1 specific multi-chain chimeric antigen receptor
US20180134795A1 (en) Cd123 specific multi-chain chimeric antigen receptor
JP2018183167A (ja) 免疫療法のための同種および免疫抑制耐性ｔ細胞を操作するための方法
JP2018504144A (ja) Ｃｌｌ１特異的多鎖キメラ抗原受容体
AU2023244350B2 (en) Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
US12577290B2 (en) FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
RU2826155C2 (ru) Индуцибельные химерные цитокиновые рецепторы
RU2775453C2 (ru) Сконструированные универсальные иммунные клетки с анти-cd22 химерным антигенным рецептором

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240719

R150 Certificate of patent or registration of utility model

Ref document number: 7526101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150